雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌阳性消化性溃疡疗效及预后分析  

Curative efficacy and prognosis of sequential therapy of rabeprazole in combination with antibiotics in treatment of Helicobacter pylori-positive peptic ulcer

作　　者：杨忠兰[1] 吴云峰[1] 田茂超[1] 

机构地区：[1]遵义市第一人民医院,贵州遵义563000

出　　处：《中国现代医学杂志》2015年第18期91-94,共4页China Journal of Modern Medicine

摘　　要：目的探讨雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡(PU)的临床疗效及预后。方法 140例符合纳入标准的Hp阳性PU患者随机分为对照组(n=70)和观察组(n=70)。对照组给予雷贝拉唑联合抗生素标准三联疗法;观察组给予雷贝拉唑联合抗生素序贯疗法。观察比较两组治疗疗效、Hp根除率、临床症状改善情况及不良反应发生情况。随访6个月,比较两组复发率。结果观察组的治疗总有效率和Hp根除率分别为95.7%和97.1%,明显高于对照组84.3%和82.8%(P<0.05)。治疗后,与对照组相比,观察组存在上腹胀痛、嗳气、反酸和恶心症状的患者例数明显减少,差异具有统计学意义(P<0.05)。治疗过程中,两组均未出现严重不良反应,不良反应发生率组间比较差异无统计学意义(P>0.05)。随访6个月,观察组的复发率为5.7%,明显低于对照组17.1%(P<0.05)。结论雷贝拉唑联合抗生素序贯疗法治疗Hp阳性PU疗效可靠,治疗有效率及Hp根除率高,能够有效缓解临床症状,并减少疾病复发,且不良反应轻微,疗效明显优于标准三联疗法,为临床上治疗Hp阳性消化性溃疡提供新的理论基础。【Objective】To investigate the clinical effect and prognosis of sequential therapy of rabeprazole in combination with antibiotics in the treatment of Helicobacter pylori（Hp）-positive peptic ulcer（PU）. 【Methods】A total of 140 cases of Hp-positive PU meeting the inclusion criteria were randomly divided into two groups with 70 cases in each group. The patients of the control group were treated with standard triple therapy of rabeprazole in combination with antibiotics, while the patients of the observation group were given sequential therapy of rabeprazole in combination with antibiotics. After six-month follow-up, the curative efficacy, Hp eradication rate, improvement of clinical symptoms, adverse reactions and recurrence rate were observed and compared.【Results】The observation group had a therapeutic efficiency rate of 95.7% and an Hp eradication rate of 97.1%, which were statistically higher than those in the control group（84.3% and 82.8%, respectively, P 〈 0.05）. After the treatment, the treatment group had fewer cases with upper abdominal distention and pain, eructation, acid regurgitation and nausea than the control group（all P 〈 0.05）. During the treatment, there was no case of severe adverse reactions, and the incidence of adverse reactions in both groups was of no statistical difference（P 〉 0.05）. In the six-month follow-up, the recurrence rate in the observation group was 5.7%, which was statistically lower than 17.1% in the control group（P 〈0.05）.【Conclusions】Sequential therapy of rabeprazole in combination with antibiotics for Hp-positive PU is effective, and could significantly improve clinical symptoms and reduce recurrence rate with mild adverse reactions and many advantages over standard triple therapy.

关 键 词：雷贝拉唑 序贯疗法 幽门螺杆菌 消化性溃疡 预后 

分 类 号：R573.1[医药卫生—消化系统]